Design and development of a novel vaccine for protection against lyme borreliosis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Comstedt, Pär ^a   Hanner, Markus ^a   Schüler, Wolfgang ^a   Meinke, Andreas ^a   Lundberg, Urban ^a  

^a Valneva Austria GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; EPITOPE; HETERODIMER; IMMUNOLOGICAL ADJUVANT; LYME DISEASE VACCINE; NEW DRUG; OUTER SURFACE PROTEIN A; PLACEBO; BACTERIAL VACCINE; LIPOPROTEIN; MEMBRANE ANTIGEN; OUTER MEMBRANE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BORRELIA; BORRELIA AFZELII; BORRELIA BAVARIENSIS; BORRELIA BURGDORFERI; BORRELIA GARINII; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISULFIDE BOND; DRUG DESIGN; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFECTION CONTROL; LIPOSOMAL DELIVERY; LYME DISEASE; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROVOCATION TEST; SEROTYPE; SPIROCHETE; STRUCTURE ACTIVITY RELATION; TEMPERATURE SENSITIVITY; THERMOSTABILITY; TICK BORNE DISEASE; ANIMAL; C3H MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; SYNTHESIS; TICK;

ANIMALS; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE; LYME DISEASE VACCINES; MICE; MICE, INBRED C3H; TICKS;

EID: 84912118097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113294     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention (2013) How many people get Lyme disease? Available: Http://www.cdc.gov/lyme/stats/humanCases.html Accessed 2014 May 27.
2. Hubalek Z (2009) Epidemiology of lyme borreliosis. Curr Probl Dermatol 37: 31-50.
3. Lindgren E, Jaenson TG, Organization WH (2006) Lyme borreliosis in Europe: Influences of climate and climate change, epidemiology, ecology and adaptation measures. Citeseer.
4. Rizzoli A, Hauffe H, Carpi G, Vourc HG, Neteler M, et al. (2011) Lyme borreliosis in Europe. Euro Surveill 16.
5. Barbour AG, Tessier SL, Todd WJ (1983) Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun 41: 795-804.
6. Bergstrom S, Bundoc VG, Barbour AG (1989) Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol 3: 479-486.
7. Ding W, Huang X, Yang X, Dunn JJ, Luft BJ, et al. (2000) Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol 302: 1153-1164.
8. Schubach WH, Mudri S, Dattwyler RJ, Luft BJ (1991) Mapping antibodybinding domains of the major outer surface membrane protein (OspA) of Borrelia burgdorferi. Infect Immun 59: 1911-1915.
9. de Silva AM, Telford SR 3rd, Brunet LR, Barthold SW, Fikrig E (1996) Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 183: 271-275.
10. Battisti JM, Bono JL, Rosa PA, Schrumpf ME, Schwan TG, et al. (2008) Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector. Infect Immun 76: 5228-5237.
11. Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, et al. (2004) Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology 150: 1741-1755.
12. Noppa L, Ostberg Y, Lavrinovicha M, Bergstrom S (2001) P13, an integral membrane protein of Borrelia burgdorferi, is C-Terminally processed and contains surface-exposed domains. Infect Immun 69: 3323-3334.
13. Fuchs H, Wallich R, Simon MM, Kramer MD (1994) The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin (ogen) receptor. Proc Natl Acad Sci U S A 91: 12594-12598.
14. Pal U, Li X, Wang T, Montgomery RR, Ramamoorthi N, et al. (2004) TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 119: 457-468.
15. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA (1995) Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A 92: 2909-2913.
16. Gipson CL, de Silva AM (2005) Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks. Infect Immun 73: 1644-1647.
17. Rathinavelu S, Broadwater A, de Silva AM (2003) Does host complement kill Borrelia burgdorferi within ticks? Infect Immun 71: 822-829.
18. Golde WT, Piesman J, Dolan MC, Kramer M, Hauser P, et al. (1997) Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 65: 882-889.
19. Koide S, Yang X, Huang X, Dunn JJ, Luft BJ (2005) Structure-based design of a second-generation Lyme disease vaccine based on a C-Terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 350: 290-299.
20. Fingerle V, Schulte-Spechtel UC, Ruzic-Sabljic E, Leonhard S, Hofmann H, et al. (2008) Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int J Med Microbiol 298: 279-290.
21. Margos G, Vollmer SA, Cornet M, Garnier M, Fingerle V, et al. (2009) A new Borrelia species defined by multilocus sequence analysis of housekeeping genes. Appl Environ Microbiol 75: 5410-5416.
22. Nadelman RB, Wormser GP (1998) Lyme borreliosis. Lancet 352: 557-565.
23. Ruzic-Sabljic E, Maraspin V, Lotric-Furlan S, Jurca T, Logar M, et al. (2002) Characterization of Borrelia burgdorferi sensu lato strains isolated from human material in Slovenia. Wien Klin Wochenschr 114: 544-550.
24. Steere AC (2001) Lyme disease. N Engl J Med 345: 115-125.
25. Wang G, van Dam AP, Dankert J (1999) Phenotypic and genetic characterization of a novel Borrelia burgdorferi sensu lato isolate from a patient with lyme borreliosis. J Clin Microbiol 37: 3025-3028.
26. Foldvari G, Farkas R, Lakos A (2005) Borrelia spielmanii erythema migrans, Hungary. Emerg Infect Dis 11: 1794-1795.
27. Maraspin V, Ruzic-Sabljic E, Strle F (2006) Lyme borreliosis and Borrelia spielmanii. Emerg Infect Dis 12: 1177.
28. Collares-Pereira M, Couceiro S, Franca I, Kurtenbach K, Schafer SM, et al. (2004) First isolation of Borrelia lusitaniae from a human patient. J Clin Microbiol 42: 1316-1318.
29. Diza E, Papa A, Vezyri E, Tsounis S, Milonas I, et al. (2004) Borrelia valaisiana in cerebrospinal fluid. Emerg Infect Dis 10: 1692-1693.
30. Strle F, Picken RN, Cheng Y, Cimperman J, Maraspin V, et al. (1997) Clinical findings for patients with Lyme borreliosis caused by Borrelia burgdorferi sensu lato with genotypic and phenotypic similarities to strain 25015. Clin Infect Dis 25: 273-280.
31. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, et al. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281: 703-706.
32. Steere AC, Drouin EE, Glickstein LJ (2011) Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 52 Suppl 3: S259-265.
33. Erdile LF, Brandt MA, Warakomski DJ, Westrack GJ, Sadziene A, et al. (1993) Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun 61: 81-90.
34. Li H, Dunn JJ, Luft BJ, Lawson CL (1997) Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc Natl Acad Sci U S A 94: 3584-3589.
35. Makabe K, Biancalana M, Yan S, Tereshko V, Gawlak G, et al. (2008) Highresolution structure of a self-Assembly-competent form of a hydrophobic peptide captured in a soluble beta-sheet scaffold. J Mol Biol 378: 459-467.
36. DeLano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA, USA. Available: Http://www.pymol.org.
37. Vinayagam A, Pugalenthi G, Rajesh R, Sowdhamini R (2004) DSDBASE: A consortium of native and modelled disulphide bonds in proteins. Nucleic Acids Res 32: D200-202.
38. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, et al. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6: 429-440.
39. Poljak A, Comstedt P, Hanner M, Schuler W, Meinke A, et al. (2012) Identification and characterization of Borrelia antigens as potential vaccine candidates against Lyme borreliosis. Vaccine 30: 4398-4406.
40. Barbour AG (1984) Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 57: 521-525.
41. Liang FT, Alvarez AL, Gu Y, Nowling JM, Ramamoorthy R, et al. (1999) An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J Immunol 163: 5566-5573.
42. Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, et al. (1990) Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci U S A 87: 3768-3772.
43. Dani VS, Ramakrishnan C, Varadarajan R (2003) MODIP revisited: Reevaluation and refinement of an automated procedure for modeling of disulfide bonds in proteins. Protein Eng 16: 187-193.
44. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T (2009) The SWISSMODEL Repository and associated resources. Nucleic Acids Res 37: D387-392.
45. Gern L, Hu CM, Voet P, Hauser P, Lobet Y (1997) Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 15: 1551-1557.
46. Fikrig E, Telford SR 3rd, Wallich R, Chen M, Lobet Y, et al. (1995) Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. J Exp Med 181: 215-221.
47. Livey I, O'Rourke M, Traweger A, Savidis-Dacho H, Crowe BA, et al. (2011) A new approach to a Lyme disease vaccine. Clin Infect Dis 52 Suppl 3: S266-270.
48. Wressnigg N, Pollabauer EM, Aichinger G, Portsmouth D, Low-Baselli A, et al. (2013) Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: A double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis 13: 680-689.
49. Schwendinger MG, O'Rourke M, Traweger A, Savidis-Dacho H, Pilz A, et al. (2013) Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model. PLoS One 8: E79022.
50. Huang X, Yang X, Luft BJ, Koide S (1998) NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies. J Mol Biol 281: 61-67.
51. Sears JE, Fikrig E, Nakagawa TY, Deponte K, Marcantonio N, et al. (1991) Molecular mapping of Osp-A mediated immunity against Borrelia burgdorferi, the agent of Lyme disease. J Immunol 147: 1995-2000.
52. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, et al. (1998) Vaccination against Lyme disease with recombinant Borrelia burgdorferi outersurface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339: 209-215.
53. Bockenstedt LK, Fikrig E, Barthold SW, Kantor FS, Flavell RA (1993) Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. J Immunol 151: 900-906.
54. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, et al. (1998) A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 339: 216-222.
55. Johnson BJ, Sviat SL, Happ CM, Dunn JJ, Frantz JC, et al. (1995) Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13: 1086-1094.